Today CosmosID announced participation in Vice President Biden’s National Cancer Moonshot, which aims to accelerate progress in preventing, diagnosing, and treating cancer. CosmosID will provide access to its automated bioinformatics platform, MetaGenID, for five cancer microbiome research studies (valued at $150,000) to understand how the microbiome (i.e. oral, gut, and skin) contributes to development of specific cancers.
{iframe}https://www.thestreet.com/story/13855631/1/cosmosid-announces-oncobiome-partnership-with-the-white-house-cancer-moonshot-initiative.html{/iframe}